国际肺动脉高压治疗药物偿付政策及对我国的启示

International Reimbursement Policies on Drugs for Pulmonary Arterial Hypertension and Enlightenment to China

目的介绍国际肺动脉高压治疗药物偿付政策,并为我国相关政策的探索提供参考。方法根据文献分析澳大利亚、加拿大、美国以及部分欧盟国家肺动脉高压治疗药物的报销情况以及偿付机制,并与国内现状进行比较。结果肺动脉高压治疗药物虽然价格昂贵,但本研究包含的国家中,大多数都对其进行报销;而我国目前只有个别城市将肺动脉高压治疗药物纳入医保,在全国范围内,该类药物可及性极差,患者面临因病致贫甚至放弃治疗的窘境。结论我国应当借鉴国际罕见病立法较早、医疗保障制度完善的国家的经验,同时剖析国内较早尝试肺动脉高压政府救助的地区的做法,推进肺动脉高压治疗药物报销。

OBJECTIVE To introduce international reimbursement policies on drugs for pulmonary arterial hypertension （PAH） , and provide a reference for establishing relevant policies in China. METHODS Reimbursement policies on PAH drugs of Australia, Canada, America and some EU countries were analyzed and compared with the status quo in China. RESULTS Although expensive, PAH drugs are reimbursed by medical insurance in most countries included in this study. However, the accessibility of PAH drugs in China remains very poor with only a few cities including these drugs in the medical insurance. Patients with PAH face with poverty caused by disease, even abandoning treatment. CONCLUSION Learning the experience from countries with rare disease act and good medical insurance system and analysing the earliest attempts to reimburse PAH drugs in China will help promote the reimbursement policy on PAH drugs in China.